Clearmind Medicine达成重大里程碑，完成FDA监管I/II期试验A部分治疗_老虎社区_美港股上老虎

Clearmind Medicine达成重大里程碑，完成FDA监管I/II期试验A部分治疗

美股速递06-22

Clearmind Medicine, Inc. 在药物研发道路上取得了一项关键进展，成功完成了其在美国食品药品监督管理局监管下的I/II期临床试验中的A部分治疗阶段。这标志着该公司在探索其候选药物的安全性与有效性方面迈出了坚实的一步，为其后续的临床开发计划奠定了重要基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1181752158?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-22 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181752158","market":"us","top_or_hot":-1,"title":"Clearmind Medicine达成重大里程碑，完成FDA监管I/II期试验A部分治疗","media":"美股速递","content":"<p>Clearmind Medicine, Inc. 在药物研发道路上取得了一项关键进展，成功完成了其在美国食品药品监督管理局监管下的I/II期临床试验中的A部分治疗阶段。这标志着该公司在探索其候选药物的安全性与有效性方面迈出了坚实的一步，为其后续的临床开发计划奠定了重要基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearmind Medicine达成重大里程碑，完成FDA监管I/II期试验A部分治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearmind Medicine达成重大里程碑，完成FDA监管I/II期试验A部分治疗\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-22 20:07 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clearmind Medicine, Inc. 在药物研发道路上取得了一项关键进展，成功完成了其在美国食品药品监督管理局监管下的I/II期临床试验中的A部分治疗阶段。这标志着该公司在探索其候选药物的安全性与有效性方面迈出了坚实的一步，为其后续的临床开发计划奠定了重要基础。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1181752158","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181752158","pubTimestamp":1782130069,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clearmind Medicine, Inc. 在药物研发道路上取得了一项关键进展，成功完成了其在美国食品药品监督管理局监管下的I/II期临床试验中的A部分治疗阶段。这标志着该公司在探索其候选药物的安全性与有效性方面迈出了坚实的一步，为其后续的临床开发计划奠定了重要基础。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","CMND":"Clearmind Medicine, Inc."},"translate_title":"Clearmind Medicine Reaches Major Milestone to Complete Part A Treatment in FDA Regulatory Phase I/II Trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMND":1},"content_text":"Clearmind Medicine, Inc. 在药物研发道路上取得了一项关键进展，成功完成了其在美国食品药品监督管理局监管下的I/II期临床试验中的A部分治疗阶段。这标志着该公司在探索其候选药物的安全性与有效性方面迈出了坚实的一步，为其后续的临床开发计划奠定了重要基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}